At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
FX006 10 mg +3 moredrug
Likely dose
FX006 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee
In Brief
A Phase 2 clinical trial evaluating FX006 10 mg, FX006 40 mg, and 2 other interventions for Osteoarthritis of the Knee. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The purpose of this study was to evaluate the safety, pharmacokinetics and pharmacodynamics of FX006 in patients with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartJul 2012
Primary CompletionNov 2012
TodayJul 2026
First PostedDec 7, 2011
Enrollment StartJul 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.6 years ago
Interventions
FX006 10 mgdrug
single 3 mL IA injection
FX006 40 mgdrug
single 3 mL IA injection
FX006 60 mgdrug
single 3 mL IA injection
TCA IR 40drug
single 1 mL IA injection